Literature DB >> 11424223

Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A.

K B Bleicher1, T R Pippert, W E Glaab, T R Skopek, J F Sina, D R Umbenhauer.   

Abstract

Exposure of rats to peroxisome proliferators induces members of the cytochrome P450 4A (CYP4A) family. In rats, the CYP4A family consists of four related genes, CYP4A1, CYP4A2, CYP4A3, and CYP4A8. We are specifically interested in examining CYP4A1, CYP4A2, and CYP4A3, each of which is expressed in a tissue-dependent and sex-dependent manner. While CYP4A1 is sufficiently different from the other two members to enable relatively easy specific quantitation, the close similarity between CYP4A2 and CYP4A3 makes quantitative discrimination difficult. We have combined a fluorescent real-time PCR assay (TaqMan) with the sequence-specific mismatch amplification mutation assay (MAMA) to allow us to carry out specific quantitation of all three members of this family. The assay is designed such that a single fluorescent TaqMan(R) probe binds to all three gene products, while specificity is conferred by sequence-specific primers. This specific MAMA technique takes advantage of the ability of Taq polymerase to distinguish between the two cDNAs based on mismatches at the 3' end of a PCR primer. In the 84-base PCR product used for this assay, there is only a single-base difference between CYP4A2 and CYP4A3. Despite this similarity, there is at least a 1000-fold discrimination between the two sequences, using CYP4A2 or CYP4A3 specific standards. Analysis of rat liver RNA from both sexes demonstrates that this discrimination is also achieved in complex RNA mixtures. This technique should be broadly applicable to other areas of research such as allelic discrimination, detecting mutational hotspots in tumors, and discrimination among closely related members of other gene families. Copyright 2001 John Wiley & Sons, Inc. J Biochem Mol Toxicol 15:133-142, 2001

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11424223     DOI: 10.1002/jbt.10

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  6 in total

1.  Development of allele-specific PCR and RT-PCR assays for clustered resistance genes using a potato late blight resistance transgene as a model.

Authors:  B P Millett; J M Bradeen
Journal:  Theor Appl Genet       Date:  2006-12-20       Impact factor: 5.699

2.  Catabolism of (2E)-4-hydroxy-2-nonenal via ω- and ω-1-oxidation stimulated by ketogenic diet.

Authors:  Zhicheng Jin; Jessica M Berthiaume; Qingling Li; Fabrice Henry; Zhong Huang; Sushabhan Sadhukhan; Peng Gao; Gregory P Tochtrop; Michelle A Puchowicz; Guo-Fang Zhang
Journal:  J Biol Chem       Date:  2014-10-01       Impact factor: 5.157

3.  Expression of CYP 4A ω-hydroxylase and formation of 20-hydroxyeicosatetreanoic acid (20-HETE) in cultured rat brain astrocytes.

Authors:  Debebe Gebremedhin; David X Zhang; Koryn A Carver; Nicole Rau; Kevin R Rarick; Richard J Roman; David R Harder
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-05-09       Impact factor: 3.072

4.  3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats.

Authors:  Mona E Aboutabl; Beshay N M Zordoky; Ayman O S El-Kadi
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

5.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Authors:  Jordan J Feld; Santosh Nanda; Ying Huang; Weiping Chen; Maggie Cam; Susan N Pusek; Lisa M Schweigler; Dickens Theodore; Steven L Zacks; T Jake Liang; Michael W Fried
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

6.  Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.

Authors:  Hassan N Althurwi; Mandy M Y Tse; Ghada Abdelhamid; Beshay N M Zordoky; Bruce D Hammock; Ayman O S El-Kadi
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.